404 related articles for article (PubMed ID: 27325479)
41. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
42. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
[TBL] [Abstract][Full Text] [Related]
43. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
[TBL] [Abstract][Full Text] [Related]
44. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M; Goergen H; Kobe C; Kuhnert G; Lohri A; Greil R; Sasse S; Topp MS; Schäfer E; Hertenstein B; Soekler M; Vogelhuber M; Zijlstra JM; Keller UB; Krause SW; Wilhelm M; Maschmeyer G; Thiemer J; Dührsen U; Meissner J; Viardot A; Eich H; Baues C; Diehl V; Rosenwald A; von Tresckow B; Dietlein M; Borchmann P; Engert A
J Clin Oncol; 2019 Nov; 37(31):2835-2845. PubMed ID: 31498753
[TBL] [Abstract][Full Text] [Related]
45. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Straus DJ; Jung SH; Pitcher B; Kostakoglu L; Grecula JC; Hsi ED; Schöder H; Popplewell LL; Chang JE; Moskowitz CH; Wagner-Johnston N; Leonard JP; Friedberg JW; Kahl BS; Cheson BD; Bartlett NL
Blood; 2018 Sep; 132(10):1013-1021. PubMed ID: 30049811
[TBL] [Abstract][Full Text] [Related]
46. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
Evens AM; Cilley J; Ortiz T; Gounder M; Hou N; Rademaker A; Miyata S; Catsaros K; Augustyniak C; Bennett CL; Tallman MS; Variakojis D; Winter JN; Gordon LI
Br J Haematol; 2007 Jun; 137(6):545-52. PubMed ID: 17459049
[TBL] [Abstract][Full Text] [Related]
47. Balancing risk and benefit in early-stage classical Hodgkin lymphoma.
Bröckelmann PJ; Sasse S; Engert A
Blood; 2018 Apr; 131(15):1666-1678. PubMed ID: 29500174
[TBL] [Abstract][Full Text] [Related]
48. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
49. Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?
Laskar S; Kumar DP; Khanna N; Menon H; Sengar M; Arora B; Gujral S; Shet T; Sridhar E; Rangarajan V; Muckaden MA; Nair R; Banavali S
Leuk Lymphoma; 2014 Oct; 55(10):2356-61. PubMed ID: 24354681
[TBL] [Abstract][Full Text] [Related]
50. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy.
Phan J; Mazloom A; Abboud M; Salehpour M; Reed V; Zreik T; Shihadeh F; Fisher C; Wogan C; Dabaja B
Am J Clin Oncol; 2011 Oct; 34(5):499-505. PubMed ID: 21537149
[TBL] [Abstract][Full Text] [Related]
51. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
Brusamolino E; Lunghi F; Orlandi E; Astori C; Passamonti F; Baraté C; Pagnucco G; Baio A; Franchini P; Lazzarino M; Bernasconi C
Haematologica; 2000 Oct; 85(10):1032-9. PubMed ID: 11025593
[TBL] [Abstract][Full Text] [Related]
52. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.
Paumier A; Ghalibafian M; Beaudre A; Ferreira I; Pichenot C; Messai T; Lessard NA; Lefkopoulos D; Girinsky T
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):199-205. PubMed ID: 21481723
[TBL] [Abstract][Full Text] [Related]
53. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
54. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease.
Aviles A; Delgado S
Clin Lab Haematol; 1998 Apr; 20(2):95-9. PubMed ID: 9681219
[TBL] [Abstract][Full Text] [Related]
55. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
[TBL] [Abstract][Full Text] [Related]
56. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
57. Treating early-stage Hodgkin lymphoma in resource-limited settings: InPOG-HL-15-01 experience.
Mahajan A; Singh M; Bakhshi S; Jain S; Radhakrishnan V; Verma N; Seth R; Arora RS; Dinand V; Kalra M; Mandal P; Kapoor G; Sajid M; Thulkar S; Arora A; Taluja A; Chandra J
Pediatr Blood Cancer; 2021 Oct; 68(10):e29219. PubMed ID: 34291860
[TBL] [Abstract][Full Text] [Related]
58. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy.
Pinnix CC; Gunther JR; Fang P; Bankston ME; Milgrom SA; Boyce D; Lee HJ; Nair R; Steiner R; Strati P; Ahmed S; Iyer SP; Westin J; Parmar S; Rodriguez MA; Nastoupil L; Neelapu S; Flowers C; Dabaja BS
JAMA Netw Open; 2020 Sep; 3(9):e2013935. PubMed ID: 32990738
[TBL] [Abstract][Full Text] [Related]
59. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease.
Reddy JP; Akhtari M; Smith GL; Pinnix C; Osborne EM; Gunther JR; Allen PK; Yehia ZA; Fanale M; Rodriguez MA; Fowler N; Milgrom SA; Wogan CF; Dabaja BS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):664-670.e2. PubMed ID: 26321471
[TBL] [Abstract][Full Text] [Related]
60. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]